A multicenter clinical trial of Gadolite Oral Suspension as a contrast agent for MRI

Daniel L. Rubin, Karen L. Falk, Malcolm J. Sperling, Michael Ross, Sanjay Saini, Barry Rothman, Frank Shellock, Elias Zerhouni, David Stark, Eric K. Outwater, Udo Schmiedl, Louis C. Kirby, Judith Chezmar, Terry L Coates, Miles Chang, Jeffery M. Silverman, Neil Rofsky, Keith Burnett, Julie Engel, Stuart W. Young

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The purpose of this study was to assess the effectiveness and safety of Gadolite Oral Suspension as a gastrointestinal (GI) contrast agent for MRI in a phase H and two phase HI multicenter clinical trials. Gadolite was administered to 306 patients with known or suspected abdominal and/or pelvic disease. MRI with T1 and T2-weighted sequences was performed before and after ingestion. Efficacy was evaluated by having two masked readers rate the certainty of their MR diagnosis (0 = uncertain, 1 = probable, 2 = definite) on randomly presented pre- and post-Gadolite Oral Suspension enhanced images. Principal investigators also evaluated the images and established the final diagnosis. Vital signs, clinical chemistries, and adverse events were documented. Blood and urine samples were analyzed for gadolinium content to determine whether Gadolite Oral Suspension was absorbed systemically. Certainty in MR diagnosis increased significantly (P < .001) for both blinded readers between pre and post-Gadolite images (.49-1.18 for reader 1; .461.53 for reader 2). Sensitivity, specificity, and accuracy also increased for both masked readers. No gadolinium was detected in blood or urine samples. There were no serious adverse events and no apparent drug-related trends in mean vital signs or laboratory values. Gadolite is a highly effective, safe, and well tolerated contrast agent for clinical use with MRI.

Original languageEnglish (US)
Pages (from-to)865-872
Number of pages8
JournalJournal of Magnetic Resonance Imaging
Volume7
Issue number5
DOIs
StatePublished - Sep 1997

Fingerprint

Contrast Media
Multicenter Studies
Suspensions
Clinical Trials
Vital Signs
Gadolinium
Urine
Gastrointestinal Agents
Clinical Chemistry
Gadolite
Eating
Research Personnel
Safety
Sensitivity and Specificity
Pharmaceutical Preparations

Keywords

  • Abdomen
  • Contrast agent
  • Gadolite
  • Gastrointestinal
  • MR
  • Pelvis

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Rubin, D. L., Falk, K. L., Sperling, M. J., Ross, M., Saini, S., Rothman, B., ... Young, S. W. (1997). A multicenter clinical trial of Gadolite Oral Suspension as a contrast agent for MRI. Journal of Magnetic Resonance Imaging, 7(5), 865-872. https://doi.org/10.1002/jmri.1880070515

A multicenter clinical trial of Gadolite Oral Suspension as a contrast agent for MRI. / Rubin, Daniel L.; Falk, Karen L.; Sperling, Malcolm J.; Ross, Michael; Saini, Sanjay; Rothman, Barry; Shellock, Frank; Zerhouni, Elias; Stark, David; Outwater, Eric K.; Schmiedl, Udo; Kirby, Louis C.; Chezmar, Judith; Coates, Terry L; Chang, Miles; Silverman, Jeffery M.; Rofsky, Neil; Burnett, Keith; Engel, Julie; Young, Stuart W.

In: Journal of Magnetic Resonance Imaging, Vol. 7, No. 5, 09.1997, p. 865-872.

Research output: Contribution to journalArticle

Rubin, DL, Falk, KL, Sperling, MJ, Ross, M, Saini, S, Rothman, B, Shellock, F, Zerhouni, E, Stark, D, Outwater, EK, Schmiedl, U, Kirby, LC, Chezmar, J, Coates, TL, Chang, M, Silverman, JM, Rofsky, N, Burnett, K, Engel, J & Young, SW 1997, 'A multicenter clinical trial of Gadolite Oral Suspension as a contrast agent for MRI', Journal of Magnetic Resonance Imaging, vol. 7, no. 5, pp. 865-872. https://doi.org/10.1002/jmri.1880070515
Rubin, Daniel L. ; Falk, Karen L. ; Sperling, Malcolm J. ; Ross, Michael ; Saini, Sanjay ; Rothman, Barry ; Shellock, Frank ; Zerhouni, Elias ; Stark, David ; Outwater, Eric K. ; Schmiedl, Udo ; Kirby, Louis C. ; Chezmar, Judith ; Coates, Terry L ; Chang, Miles ; Silverman, Jeffery M. ; Rofsky, Neil ; Burnett, Keith ; Engel, Julie ; Young, Stuart W. / A multicenter clinical trial of Gadolite Oral Suspension as a contrast agent for MRI. In: Journal of Magnetic Resonance Imaging. 1997 ; Vol. 7, No. 5. pp. 865-872.
@article{37918e16d92a45638fa2dbd66c86a491,
title = "A multicenter clinical trial of Gadolite Oral Suspension as a contrast agent for MRI",
abstract = "The purpose of this study was to assess the effectiveness and safety of Gadolite Oral Suspension as a gastrointestinal (GI) contrast agent for MRI in a phase H and two phase HI multicenter clinical trials. Gadolite was administered to 306 patients with known or suspected abdominal and/or pelvic disease. MRI with T1 and T2-weighted sequences was performed before and after ingestion. Efficacy was evaluated by having two masked readers rate the certainty of their MR diagnosis (0 = uncertain, 1 = probable, 2 = definite) on randomly presented pre- and post-Gadolite Oral Suspension enhanced images. Principal investigators also evaluated the images and established the final diagnosis. Vital signs, clinical chemistries, and adverse events were documented. Blood and urine samples were analyzed for gadolinium content to determine whether Gadolite Oral Suspension was absorbed systemically. Certainty in MR diagnosis increased significantly (P < .001) for both blinded readers between pre and post-Gadolite images (.49-1.18 for reader 1; .461.53 for reader 2). Sensitivity, specificity, and accuracy also increased for both masked readers. No gadolinium was detected in blood or urine samples. There were no serious adverse events and no apparent drug-related trends in mean vital signs or laboratory values. Gadolite is a highly effective, safe, and well tolerated contrast agent for clinical use with MRI.",
keywords = "Abdomen, Contrast agent, Gadolite, Gastrointestinal, MR, Pelvis",
author = "Rubin, {Daniel L.} and Falk, {Karen L.} and Sperling, {Malcolm J.} and Michael Ross and Sanjay Saini and Barry Rothman and Frank Shellock and Elias Zerhouni and David Stark and Outwater, {Eric K.} and Udo Schmiedl and Kirby, {Louis C.} and Judith Chezmar and Coates, {Terry L} and Miles Chang and Silverman, {Jeffery M.} and Neil Rofsky and Keith Burnett and Julie Engel and Young, {Stuart W.}",
year = "1997",
month = "9",
doi = "10.1002/jmri.1880070515",
language = "English (US)",
volume = "7",
pages = "865--872",
journal = "Journal of Magnetic Resonance Imaging",
issn = "1053-1807",
publisher = "John Wiley and Sons Inc.",
number = "5",

}

TY - JOUR

T1 - A multicenter clinical trial of Gadolite Oral Suspension as a contrast agent for MRI

AU - Rubin, Daniel L.

AU - Falk, Karen L.

AU - Sperling, Malcolm J.

AU - Ross, Michael

AU - Saini, Sanjay

AU - Rothman, Barry

AU - Shellock, Frank

AU - Zerhouni, Elias

AU - Stark, David

AU - Outwater, Eric K.

AU - Schmiedl, Udo

AU - Kirby, Louis C.

AU - Chezmar, Judith

AU - Coates, Terry L

AU - Chang, Miles

AU - Silverman, Jeffery M.

AU - Rofsky, Neil

AU - Burnett, Keith

AU - Engel, Julie

AU - Young, Stuart W.

PY - 1997/9

Y1 - 1997/9

N2 - The purpose of this study was to assess the effectiveness and safety of Gadolite Oral Suspension as a gastrointestinal (GI) contrast agent for MRI in a phase H and two phase HI multicenter clinical trials. Gadolite was administered to 306 patients with known or suspected abdominal and/or pelvic disease. MRI with T1 and T2-weighted sequences was performed before and after ingestion. Efficacy was evaluated by having two masked readers rate the certainty of their MR diagnosis (0 = uncertain, 1 = probable, 2 = definite) on randomly presented pre- and post-Gadolite Oral Suspension enhanced images. Principal investigators also evaluated the images and established the final diagnosis. Vital signs, clinical chemistries, and adverse events were documented. Blood and urine samples were analyzed for gadolinium content to determine whether Gadolite Oral Suspension was absorbed systemically. Certainty in MR diagnosis increased significantly (P < .001) for both blinded readers between pre and post-Gadolite images (.49-1.18 for reader 1; .461.53 for reader 2). Sensitivity, specificity, and accuracy also increased for both masked readers. No gadolinium was detected in blood or urine samples. There were no serious adverse events and no apparent drug-related trends in mean vital signs or laboratory values. Gadolite is a highly effective, safe, and well tolerated contrast agent for clinical use with MRI.

AB - The purpose of this study was to assess the effectiveness and safety of Gadolite Oral Suspension as a gastrointestinal (GI) contrast agent for MRI in a phase H and two phase HI multicenter clinical trials. Gadolite was administered to 306 patients with known or suspected abdominal and/or pelvic disease. MRI with T1 and T2-weighted sequences was performed before and after ingestion. Efficacy was evaluated by having two masked readers rate the certainty of their MR diagnosis (0 = uncertain, 1 = probable, 2 = definite) on randomly presented pre- and post-Gadolite Oral Suspension enhanced images. Principal investigators also evaluated the images and established the final diagnosis. Vital signs, clinical chemistries, and adverse events were documented. Blood and urine samples were analyzed for gadolinium content to determine whether Gadolite Oral Suspension was absorbed systemically. Certainty in MR diagnosis increased significantly (P < .001) for both blinded readers between pre and post-Gadolite images (.49-1.18 for reader 1; .461.53 for reader 2). Sensitivity, specificity, and accuracy also increased for both masked readers. No gadolinium was detected in blood or urine samples. There were no serious adverse events and no apparent drug-related trends in mean vital signs or laboratory values. Gadolite is a highly effective, safe, and well tolerated contrast agent for clinical use with MRI.

KW - Abdomen

KW - Contrast agent

KW - Gadolite

KW - Gastrointestinal

KW - MR

KW - Pelvis

UR - http://www.scopus.com/inward/record.url?scp=13144254223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13144254223&partnerID=8YFLogxK

U2 - 10.1002/jmri.1880070515

DO - 10.1002/jmri.1880070515

M3 - Article

C2 - 9307913

AN - SCOPUS:13144254223

VL - 7

SP - 865

EP - 872

JO - Journal of Magnetic Resonance Imaging

JF - Journal of Magnetic Resonance Imaging

SN - 1053-1807

IS - 5

ER -